By Josh White
Date: Thursday 26 Sep 2024
(Sharecast News) - ValiRx said in an update on Thursday that it has concluded its evaluation project with the University of Barcelona, focussed on early-stage cancer therapeutics targeting the 'KRAS2' series of drug candidates.
The AIM-traded firm said that despite promising initial results from a range of in-silico and in-vitro tests...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news